The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy.

Ramagopalan, Sreeram; Leahy, Thomas P; Ray, Joshua; Wilkinson, Samantha; Sammon, Cormac; Subbiah, Vivek

Ramagopalan, Sreeram; Leahy, Thomas P; Ray, Joshua; Wilkinson, Samantha; Sammon, Cormac; Subbiah, Vivek.

Affiliation

Ramagopalan S; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland. sreeram.ramagopalan@roche.com.
Leahy TP; PHMR Ltd., Westport, Ireland.
Ray J; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.
Wilkinson S; Roche Products Ltd, Welwyn Garden City, UK.
Sammon C; PHMR Ltd., Westport, Ireland.
Subbiah V; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, UT MD Anderson Cancer Center, Houston, USA.

BMC Med ; 19(1): 209, 2021 09 15.

Article in En | MEDLINE | ID: mdl-34521405

Subject(s)

Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung/therapy; Humans; Immunotherapy; Lung Neoplasms/therapy; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins/genetics

Key words

Immunotherapy; Innovation; Lung cancer; NSCLC; Targeted therapy

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: BMC Med Journal subject: MEDICINA Year: 2021 Type: Article Affiliation country: Switzerland

Fulltext

XML

PubMed Links

Search on Google